Recursion Pharmaceuticals bounced back by 8.72 percent on Tuesday to close at $5.36 apiece following news that it acquired a ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connect with a previously announced streamlining of the AI biotech’s pipeline.

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. | Recursion is ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning ...

Recursion states that REC-1245 is the first program using the company’s end-to-end AI platform, spanning discovery, biology, chemistry, and the clinic. According to Chris Gibson, CEO of ...

Recursion will release proof-of-concept clinical trial data over the next 12 months; investor interest in seeing if AI can speed drug development is high.

Reason to sell 1: No results to show for it Though Recursion Pharmaceuticals' platform seems promising in theory, investors will ultimately want to see results -- tangible evidence that its ...

Modern network security applications, such as network-based intrusion detection systems (NIDS) and firewalls, routinely employ deep packet inspection to identify malicious traffic. In deep packet ...

Scientists have discovered that, when a DNA-reading enzyme moves backwards along a gene, it may do so to help control when the gene is turned on.